A Phase 1 interventional study of Cobimetinib and vemurafenib in Malignant Melanoma, sponsored by Hoffmann-La Roche. Completed at 10 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-07-29.
Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing cobimetinib in Melanoma — 3 open to participants now, 6 under way, 1 of them phase 3. cobimetinib · Melanoma.
Among the 27 studies testing cobimetinib in Melanoma, this one is the 5th largest by enrollment, is the only one that started in 2011, is one of 5 in phase 1, and was the 1st registered.
3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.
Browse Melanoma studies →3 of the 27 studies testing cobimetinib in Melanoma are open now, in 3 countries. Recruiting first, the newest first:
Hanmi Pharmaceutical Company Limited · Sites in Korea, Republic of
Ages 19+
N.N. Petrov National Medical Research Center of Oncology · Sites in Russian Federation
Ages 18–85 · Healthy volunteers
Cancer Research UK · Sites in United Kingdom
Ages 18+
By country, each count listing its studies:
cobimetinib: first FDA approval 2015 (COTELLIC), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, cobimetinib is the treatment under test here. Read study by study →
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 19 · Phase 3 4
First in 2011; this study’s year is marked. 1 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 131 is above the median of 40 across 2,651 interventional studies indexed under Melanoma.
Median enrollment 45 across the 27 interventional studies. Of the 17 that completed or were terminated, 9 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 27 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
57 studies in Melanoma by Hoffmann-La Roche: none open now, 4 under way, none of them phase 3. Of 52 finished, 34 (65%) have results posted.
Among the 57 studies in Melanoma by Hoffmann-La Roche, this one is the 17th largest by enrollment of the 52 interventional ones that give a count, is one of 5 that started in 2011, is one of 27 in phase 1, and was the 13th registered.
Hoffmann-La Roche’s Melanoma studies by the year they started, since 2004.
1 of the studies testing cobimetinib in Melanoma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04835805Genentech, Inc.A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma. | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 27 studies testing cobimetinib in Melanoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 57 in Melanoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This open-label, dose-escalation study of vemurafenib in combination with cobimetinib will evaluate the safety, tolerability and pharmacokinetics in participants with BRAFV600 mutation-positive metastatic melanoma. Participants with previously untreated, BRAFV600E mutation-positive, locally advanced/unresectable or metastatic melanoma or those who have progressed on vemurafenib monotherapy immediately prior to enrolling in this trial are eligible. Participants will be assigned to different cohorts with escalating oral doses of vemurafenib and cobimetinib. This study consists of 2 stages, Stage 1 (Dose Escalation Stage [DES] and Cohort Expansion Stage [CES]) and the anticipated time on study treatment is until disease progression, unacceptable toxicity or any other discontinuation criterion is met.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive oral 60 milligrams (mg) cobimetinib once daily (QD) on Days 1-14, followed by 14 days off on Days 15-28 (14/14 dosing schedule) and oral 720 mg vemurafenib twice daily (BID) on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
Drug: Cobimetinib · Drug: vemurafenib
Participants will receive oral 60 mg cobimetinib QD on Days 1-21, followed by 7 days off on Days 22-28 (21/7 dosing schedule) and oral 720 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
Drug: Cobimetinib · Drug: vemurafenib
Participants will receive oral 60 mg cobimetinib QD on 21/7 dosing schedule and oral 960 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
Drug: Cobimetinib · Drug: vemurafenib
Participants will receive oral 60 mg cobimetinib QD on Days 1-28 (28/0 dosing schedule) and oral 720 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
Drug: Cobimetinib · Drug: vemurafenib
Participants will receive oral 60 mg cobimetinib QD on 28/0 dosing schedule and oral 960 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
Drug: Cobimetinib · Drug: vemurafenib
Participants will receive oral 80 mg cobimetinib QD on 14/14 dosing schedule and oral 720 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
Drug: Cobimetinib · Drug: vemurafenib
Participants will receive oral 100 mg cobimetinib QD on 14/14 dosing schedule and oral 720 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
Drug: Cobimetinib · Drug: vemurafenib
Participants will receive oral 60 mg cobimetinib QD on 14/14 dosing schedule and oral 960 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
Drug: Cobimetinib · Drug: vemurafenib
Participants will receive oral 80 mg cobimetinib QD on 14/14 dosing schedule and oral 960 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
Drug: Cobimetinib · Drug: vemurafenib
Participants will receive oral 60 mg cobimetinib QD on 21/7 dosing schedule, or oral 100 mg cobimetinib QD on 14/14 dosing schedule of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
Drug: Cobimetinib
Participants will receive oral 60 mg cobimetinib QD on 21/7 dosing schedule and oral 720 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
Drug: Cobimetinib · Drug: vemurafenib
Participants will receive oral 60 mg cobimetinib QD on 21/7 dosing schedule and oral 960 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
Drug: Cobimetinib · Drug: vemurafenib
Participants will receive cobimetinib 60 to 100 mg at any of the 3 dosing schedules with or without vemurafenib in cycles of 28 days each until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
Also known as: GDC-0973
Participants will receive vemurafenib 720 or 960 mg along with cobimetinib in cycles of 28 days each until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
Number of Participants With Dose-Limiting Toxicities (DLTs) During DES in Combination Cohorts
DLT is defined as 1 of the following toxicities considered by the investigator to be related to study treatment: a) Grade 3 nausea, vomiting or diarrhea that resolved to Grade less than or equal to (≤) 1 within 7 days, b) Grade 3 rash or photosensitivity that resolved to Grade ≤2 within 7 days, c) Grade 3 cutaneous squamous cell carcinoma (cuSCC) that was subsequently resected, d) Grade greater than or equal to (≥) 3 fatigue or hyperuricemia that resolved to Grade ≤2 within 7 days, e) Grade 3 fever, f) Grade 3 or 4 elevation of serum creatine phosphokinase (CPK) levels, which is asymptomatic, deemed by the investigator to be clinically insignificant and that returned to Grade ≤2 during the 14-day cobimetinib treatment holiday, g) Grade ≥3 febrile neutropenia, h) Grade ≥4 neutropenia (absolute neutrophil count \[ANC\] less than \<500/microliter \[μL\]), i) Grade ≥4 thrombocytopenia, j) Grade ≥4 anemia, k) Grade ≥3 elevation of total bilirubin, hepatic transaminase or alkaline phosphatase.
Time frame: 28 Days
Maximum Tolerated Doses (MTD) of Vemurafenib and Cobimetinib When Administered in Combination in DES
The highest dose level(s) at which fewer than one-third of participants experienced a DLT was declared the MTD. DLT is defined as 1 of the following toxicities considered by the investigator to be related to study treatment: a) Grade 3 nausea, vomiting or diarrhea that resolved to Grade ≤1 within 7 days, b) Grade 3 rash/photosensitivity that resolved to Grade ≤2 within 7 days, c) Grade 3 cuSCC that was subsequently resected, d) Grade ≥3 fatigue/hyperuricemia that resolved to Grade ≤2 within 7 days, e) Grade 3 fever, f) Grade 3 or 4 elevation of serum CPK levels, which is asymptomatic, deemed to be clinically insignificant and returns to Grade ≤2 during the 14-day cobimetinib treatment holiday, g) Grade ≥3 febrile neutropenia, h) Grade ≥4 neutropenia (ANC \<500/ μL), i) Grade ≥4 thrombocytopenia, j) Grade ≥4 anemia, k) Grade ≥3 elevation of total bilirubin, hepatic transaminase or alkaline phosphatase.
Time frame: 28 Days
Maximum Plasma Concentration (Cmax) of Cobimetinib on Day 1, Cycle 1
Time frame: Cycle 1: predose (0 hours [hr]) on Days 1, 2; 0.5, 1, 2, 4, 6 hr postdose on Day 1
Cmax of Cobimetinib on Day 1, Cycle 1 in Cohort 3
Time frame: Cycle 1: predose (0 hr) on Days 1, 2; 0.5, 1, 2, 4, 6 hr postdose on Day 1
Time Taken to Reach Maximum Plasma Concentration (Tmax) of Cobimetinib on Day 1, Cycle 1
Time frame: Cycle 1: predose (0 hr) on Days 1, 2; 0.5, 1, 2, 4, 6 hr postdose on Day 1
Area Under Concentration Versus Time Curve (AUC) Over a Period of 24 Hours (AUC0-24) of Cobimetinib on Day 1, Cycle 1
Time frame: Cycle 1: predose (0 hr) on Days 1, 2; 0.5, 1, 2, 4, 6 hr postdose on Day 1
AUC0-24 of Cobimetinib on Day 1, Cycle 1 of Cohort 3
Time frame: Cycle 1: predose (0 hr) on Days 1, 2; 0.5, 1, 2, 4, 6 hr postdose on Day 1
Cmax of Cobimetinib on Day 14 (Steady State), Cycle 1
Time frame: Cycle 1: predose (0 hr) on Days 8, 14; 0.5, 1, 2, 4, 6 hr postdose on Day 14
Tmax of Cobimetinib on Day 14 (Steady State), Cycle 1
Time frame: Cycle 1: predose (0 hr) on Days 8, 14; 0.5, 1, 2, 4, 6 hr postdose on Day 14
AUC0-24 of Cobimetinib on Day 14, Cycle 1
Time frame: Cycle 1: predose (0 hr) on Days 8, 14; 0.5, 1, 2, 4, 6 hr postdose on Day 14
Clearance (CL) of Cobimetinib on Day 14 (Steady State), Cycle 1
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.
Time frame: Cycle 1: predose (0 hr) on Days 8, 14; 0.5, 1, 2, 4, 6 hr postdose on Day 14
Cmax of Vemurafenib on Day -1, Cycle 1 in Participants Previously Treated With Vemurafenib Prior to Enrollment Into This Study
Time frame: Predose (0 hr) on Days -1, 1; 2, 4, 6, 8 hr postdose on Day -1
Cmax of Vemurafenib on Day -1, Cycle 1 of Cohorts 1C and 2A in Participants Previously Treated With Vemurafenib Prior to Enrollment Into This Study
Time frame: Predose (0 hr) on Day -1, 1; 2, 4, 6, 8 hr postdose on Day -1
Tmax of Vemurafenib on Day -1, Cycle 1 in Participants Previously Treated With Vemurafenib Prior to Enrollment Into This Study
Time frame: Predose (0 hr) on Day -1, 1; 2, 4, 6, 8 hr postdose on Day -1
Cmax of Vemurafenib on Day 1, Cycle 1 in BRAFi-naïve Participants
Time frame: Predose (0 hr) on Day 1, 2; 0.5, 1, 2, 4, 6 hr postdose on Day 1
Cmax of Vemurafenib on Day 1, Cycle 1 in Cohort 1A in BRAFi-naïve Participants
Time frame: Predose (0 hr) on Day 1, 2; 0.5, 1, 2, 4, 6 hr postdose on Day 1
Tmax of Vemurafenib on Day 1, Cycle 1 in BRAFi-naïve Participants
Time frame: Predose (0 hr) on Day 1, 2; 0.5, 1, 2, 4, 6 hr postdose on Day 1
Cmax of Vemurafenib on Day 14, Cycle 1
Time frame: Predose (0 hr) on Days 14, 15; 0.5, 1, 2, 4, 6, 8 hr postdose on Day 14
Tmax of Vemurafenib on Day 14, Cycle 1
Time frame: Predose (0 hr) on Days 14, 15; 0.5, 1, 2, 4, 6, 8 hr postdose on Day 14
Percentage of Participants With an Objective Response of Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version (V) 1.1
Tumor response of CR or PR is considered as objective response. CR: disappearance of all target lesions, reduction in short axis \<10 millimeters in pathological lymph nodes (target and non-target lesions); PR: at least a 30 percent (%) decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter. Responses were confirmed by repeat assessments ≥4 weeks after initial documentation.
Time frame: Assessed at screening (within 28 days prior to initiation of Cycle 1), every 6 weeks thereafter until disease progression (up to 82 months)
Percentage of Participants With Disease Progression According to RECIST V 1.1
Progressive disease (PD) according to RECIST V 1.1: at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum on study (nadir), including baseline; in addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm; appearance of 1 or more lesions is also considered as progression.
Time frame: Assessed at screening (within 28 days prior to initiation of Cycle 1), every 6 weeks thereafter until disease progression or death (up to 82 months)
Median Duration of Response (DOR)
Duration of response, defined as the time from first occurrence of a documented objective response until the time of disease progression, as determined by investigator review of tumor assessments using RECIST v 1.1, or death from any cause during the study (that is within 30 days after the last dose of study treatment).
Time frame: Time from first occurrence of objective response until the time of disease progression or death from any cause (up to 82 months)
Overall Survival (OS)
OS was defined as the time from the date of randomization to the date of death due to any cause. Participants were censored at the last date of tumor measurement, the last date in the study drug log, or the date of last follow-up. OS analyzed using Kaplan-Meier estimate.
Time frame: Assessed at screening (within 28 days prior to initiation of Cycle 1), every 6 weeks thereafter until disease progression or death (up to 82 months)
Average Percent Change From Baseline in Fluorodeoxyglucose-positron Emission Tomography (FDG-PET) at Cycle 1 and Cycle 2
The pharmacodynamic effect of cobimetinib in combination with vemurafenib was assessed by measuring changes in FDG uptake as characterized by the lean body mass corrected (LBM) maximum standardized uptake value (SUV max) measurement using FDG-PET. Post-baseline timepoint Cycle 1 was averaged between Days 10 to 14 and Cycle 2 for Days 14+7.
Time frame: Cycle 1 (Days 10 to 14), Cycle 2 (Days 14+7)
Pharmacodynamics: Number of Participants With Mitogen-Activated Protein Kinase (MAPK) Inhibition, as Assessed by Immunohistochemistry (IHC)
Changes in effector molecules of the MAPK pathway that are directly or indirectly affected by BRAF and MEK inhibition (including but not limited to ERK and phosphorylated ERK and MEK) by IHC using biopsies at baseline, between Days 10-14 of Cycle 1, and at disease progression. IHC is a staining process performed on fresh/frozen tumor tissue samples.
Time frame: At baseline; Cycle 1: Day 14; at disease progression (Up to 32 months)
Study included two stages. Stage 1: dose escalation stage (DES), consisted of 9 "Cobimetinib + Vemurafenib" combination arms and 1 Cobimetinib monotherapy. Stage 2: cohort expansion stage (CES), consisted of 2 "Cobimetinib + Vemurafenib" combination arms, treated with recommended phase 2 dose.
| Milestone | Vemurafenib PD Participants | BRAFi-naïve Participants | Cobimetinib Monotherapy (100 mg or 60 mg) |
|---|---|---|---|
| Started | 66 | 63 | 2 |
| Completed | 11 | 24 | 0 |
| Not completed | 55 | 39 | 2 |
| Withdrew: Progressive disease | 0 | 0 | 2 |
| Withdrew: Death | 53 | 34 | 0 |
| Withdrew: Withdrawal by subject | 1 | 5 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
DLT is defined as 1 of the following toxicities considered by the investigator to be related to study treatment: a) Grade 3 nausea, vomiting or diarrhea that resolved to Grade less than or equal to (≤) 1 within 7 days, b) Grade 3 rash or photosensitivity that resolved to Grade ≤2 within 7 days, c) Grade 3 cutaneous squamous cell carcinoma (cuSCC) that was subsequently resected, d) Grade greater than or equal to (≥) 3 fatigue or hyperuricemia that resolved to Grade ≤2 within 7 days, e) Grade 3 fever, f) Grade 3 or 4 elevation of serum creatine phosphokinase (CPK) levels, which is asymptomatic, deemed by the investigator to be clinically insignificant and that returned to Grade ≤2 during the 14-day cobimetinib treatment holiday, g) Grade ≥3 febrile neutropenia, h) Grade ≥4 neutropenia (absolute neutrophil count \[ANC\] less than \<500/microliter \[μL\]), i) Grade ≥4 thrombocytopenia, j) Grade ≥4 anemia, k) Grade ≥3 elevation of total bilirubin, hepatic transaminase or alkaline phosphatase.
| participants | DES (Cohort 1): 60 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 1A): 60 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 1B): 60 mg Cobimetinib + 960 mg Vemurafenib | DES (Cohort 1C): 60 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 1D): 60 mg Cobimetinib + 960 mg Vemurafenib | DES (Cohort 2): 80 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 2A): 100 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 3): 60 mg Cobimetinib + 960 mg Vemurafenib | DES (Cohort 4): 80 mg Cobimetinib + 960 mg Vemurafenib |
|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Dose-Limiting Toxicities (DLTs) During DES in Combination Cohorts | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 1 |
The highest dose level(s) at which fewer than one-third of participants experienced a DLT was declared the MTD. DLT is defined as 1 of the following toxicities considered by the investigator to be related to study treatment: a) Grade 3 nausea, vomiting or diarrhea that resolved to Grade ≤1 within 7 days, b) Grade 3 rash/photosensitivity that resolved to Grade ≤2 within 7 days, c) Grade 3 cuSCC that was subsequently resected, d) Grade ≥3 fatigue/hyperuricemia that resolved to Grade ≤2 within 7 days, e) Grade 3 fever, f) Grade 3 or 4 elevation of serum CPK levels, which is asymptomatic, deemed to be clinically insignificant and returns to Grade ≤2 during the 14-day cobimetinib treatment holiday, g) Grade ≥3 febrile neutropenia, h) Grade ≥4 neutropenia (ANC \<500/ μL), i) Grade ≥4 thrombocytopenia, j) Grade ≥4 anemia, k) Grade ≥3 elevation of total bilirubin, hepatic transaminase or alkaline phosphatase.
| mg | Dose Escalation Stage (Stage 1) |
|---|---|
| Cobimetinib dose (21/7 dosing schedule) | 60 |
| Vemurafenib dose (21/7 dosing schedule) | 960 |
| nanograms per milliliter (ng/mL) | DES (Cohort 1): 60 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 1A): 60 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 1B): 60 mg Cobimetinib + 960 mg Vemurafenib | DES (Cohort 1C): 60 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 1D): 60 mg Cobimetinib + 960 mg Vemurafenib | DES (Cohort 2): 80 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 2A): 100 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 4): 80 mg Cobimetinib + 960 mg Vemurafenib | CES (Cohort 1A): 60 mg Cobimetinib + 720 mg Vemurafenib | CES (Cohort 1B): 60 mg Cobimetinib + 960 mg Vemurafenib |
|---|---|---|---|---|---|---|---|---|---|---|
| Maximum Plasma Concentration (Cmax) of Cobimetinib on Day 1, Cycle 1 | 159 ± 110 | 146 ± 100 | 121 ± 96 | 136 ± 81 | 130 ± 53 | 133 ± 37 | 146 ± 79 | 93.6 ± 26 | 84.3 ± 67 | 105 ± 64 |
| ng/mL | DES (Cohort 3): 60 mg Cobimetinib + 960 mg Vemurafenib |
|---|---|
| Cmax of Cobimetinib on Day 1, Cycle 1 in Cohort 3 | 51.6 ± 50.1 |
| hours | DES (Cohort 1): 60 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 1A): 60 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 1B): 60 mg Cobimetinib + 960 mg Vemurafenib | DES (Cohort 1C): 60 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 1D): 60 mg Cobimetinib + 960 mg Vemurafenib | DES (Cohort 2): 80 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 2A): 100 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 3): 60 mg Cobimetinib + 960 mg Vemurafenib | DES (Cohort 4): 80 mg Cobimetinib + 960 mg Vemurafenib | CES (Cohort 1A): 60 mg Cobimetinib + 720 mg Vemurafenib | CES (Cohort 1B): 60 mg Cobimetinib + 960 mg Vemurafenib |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Time Taken to Reach Maximum Plasma Concentration (Tmax) of Cobimetinib on Day 1, Cycle 1 | 4.00 (2.0 to 5.5) | 4.0 (2.0 to 27) | 4.00 (1.0 to 25) | 2.03 (2.0 to 24) | 3.99 (1.0 to 6.2) | 4.02 (4.0 to 4.1) | 4.03 (4.0 to 4.3) | 3.05 (2.0 to 4.1) | 4.00 (2.0 to 6.0) | 4.00 (0.5 to 6.0) | 4.00 (1.0 to 24) |
| nanograms*hours per milliliter (ng*h/mL) | DES (Cohort 1): 60 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 1A): 60 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 1B): 60 mg Cobimetinib + 960 mg Vemurafenib | DES (Cohort 1C): 60 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 1D): 60 mg Cobimetinib + 960 mg Vemurafenib | DES (Cohort 2): 80 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 2A): 100 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 4): 80 mg Cobimetinib + 960 mg Vemurafenib | CES (Cohort 1A): 60 mg Cobimetinib + 720 mg Vemurafenib | CES (Cohort 1B): 60 mg Cobimetinib + 960 mg Vemurafenib |
|---|---|---|---|---|---|---|---|---|---|---|
| Area Under Concentration Versus Time Curve (AUC) Over a Period of 24 Hours (AUC0-24) of Cobimetinib on Day 1, Cycle 1 | 2280 ± 90 | 1990 ± 99 | 1790 ± 88 | 1300 ± 35 | 1850 ± 35 | 1600 ± 29 | 2300 ± 100 | 1410 ± 29 | 1220 ± 63 | 1530 ± 65 |
| ng*h/mL | DES (Cohort 3): 60 mg Cobimetinib + 960 mg Vemurafenib |
|---|---|
| AUC0-24 of Cobimetinib on Day 1, Cycle 1 of Cohort 3 | 727 ± 556 |
| ng/mL | DES (Cohort 1): 60 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 1A): 60 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 1B): 60 mg Cobimetinib + 960 mg Vemurafenib | DES (Cohort 1C): 60 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 1D): 60 mg Cobimetinib + 960 mg Vemurafenib | DES (Cohort 2): 80 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 2A): 100 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 3): 60 mg Cobimetinib + 960 mg Vemurafenib | DES (Cohort 4): 80 mg Cobimetinib + 960 mg Vemurafenib | CES (Cohort 1A): 60 mg Cobimetinib + 720 mg Vemurafenib | CES (Cohort 1B): 60 mg Cobimetinib + 960 mg Vemurafenib |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cmax of Cobimetinib on Day 14 (Steady State), Cycle 1 | 342 ± 130 | 307 ± 75 | 232 ± 80 | 239 ± 14 | 414 ± 16 | 195 ± 48 | 383 ± 50 | 215 ± 19 | 350 ± 37 | 177 ± 74 | 200 ± 91 |
| hours | DES (Cohort 1): 60 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 1A): 60 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 1B): 60 mg Cobimetinib + 960 mg Vemurafenib | DES (Cohort 1C): 60 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 1D): 60 mg Cobimetinib + 960 mg Vemurafenib | DES (Cohort 2): 80 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 2A): 100 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 3): 60 mg Cobimetinib + 960 mg Vemurafenib | DES (Cohort 4): 80 mg Cobimetinib + 960 mg Vemurafenib | CES (Cohort 1A): 60 mg Cobimetinib + 720 mg Vemurafenib | CES (Cohort 1B): 60 mg Cobimetinib + 960 mg Vemurafenib |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Tmax of Cobimetinib on Day 14 (Steady State), Cycle 1 | 2.0 (0.98 to 4.0) | 3.98 (2.0 to 7.0) | 4.02 (0.5 to 8.0) | 4.00 (4.0 to 4.1) | 6.00 (4.9 to 6.1) | 6.0 (2.0 to 6.0) | 4.03 (2.2 to 6.1) | 4.08 (4.0 to 6.1) | 4.00 (3.9 to 4.1) | 4.04 (2.0 to 8.0) | 4.00 (0.0 to 8.0) |
| ng*h/mL | DES (Cohort 1): 60 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 1A): 60 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 1B): 60 mg Cobimetinib + 960 mg Vemurafenib | DES (Cohort 1C): 60 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 1D): 60 mg Cobimetinib + 960 mg Vemurafenib | DES (Cohort 2): 80 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 2A): 100 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 3): 60 mg Cobimetinib + 960 mg Vemurafenib | DES (Cohort 4): 80 mg Cobimetinib + 960 mg Vemurafenib | CES (Cohort 1A): 60 mg Cobimetinib + 720 mg Vemurafenib | CES (Cohort 1B): 60 mg Cobimetinib + 960 mg Vemurafenib |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AUC0-24 of Cobimetinib on Day 14, Cycle 1 | 5180 ± 170 | 4800 ± 76 | 3540 ± 83 | 4500 ± 17 | 7020 ± 27 | 3820 ± 48 | 6360 ± 46 | 3520 ± 35 | 5790 ± 36 | 2540 ± 84 | 3220 ± 124 |
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.
| Liters per hour (L/h) | DES (Cohort 1): 60 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 1A): 60 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 1B): 60 mg Cobimetinib + 960 mg Vemurafenib | DES (Cohort 1C): 60 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 1D): 60 mg Cobimetinib + 960 mg Vemurafenib | DES (Cohort 2): 80 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 2A): 100 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 3): 60 mg Cobimetinib + 960 mg Vemurafenib | DES (Cohort 4): 80 mg Cobimetinib + 960 mg Vemurafenib | CES (Cohort 1A): 60 mg Cobimetinib + 720 mg Vemurafenib | CES (Cohort 1B): 60 mg Cobimetinib + 960 mg Vemurafenib |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Clearance (CL) of Cobimetinib on Day 14 (Steady State), Cycle 1 | 11.6 ± 170 | 12.5 ± 76 | 17.0 ± 83 | 13.3 ± 17 | 8.55 ± 27 | 21.0 ± 48 | 15.7 ± 46 | 17.0 ± 35 | 13.8 ± 36 | 23.6 ± 84 | 18.6 ± 124 |
| micrograms per milliliter (mcg/mL) | DES (Cohort 1): 60 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 1A): 60 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 1B): 60 mg Cobimetinib + 960 mg Vemurafenib | DES (Cohort 2): 80 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 3): 60 mg Cobimetinib + 960 mg Vemurafenib | DES (Cohort 4): 80 mg Cobimetinib + 960 mg Vemurafenib | CES (Cohort 1A): 60 mg Cobimetinib + 720 mg Vemurafenib | CES (Cohort 1B): 60 mg Cobimetinib + 960 mg Vemurafenib |
|---|---|---|---|---|---|---|---|---|
| Cmax of Vemurafenib on Day -1, Cycle 1 in Participants Previously Treated With Vemurafenib Prior to Enrollment Into This Study | 36.4 ± 58 | 34.3 ± 34 | 60.9 ± 32 | 56.0 ± 16 | 36.4 ± 19 | 48.2 ± NA | 40.9 ± 110 | 48.6 ± 37 |
| mcg/mL | DES (Cohort 1C): 60 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 2A): 100 mg Cobimetinib + 720 mg Vemurafenib |
|---|---|---|
| Cmax of Vemurafenib on Day -1, Cycle 1 of Cohorts 1C and 2A in Participants Previously Treated With Vemurafenib Prior to Enrollment Into This Study | 38.8 ± 9.61 | 48.8 ± 35.4 |
| hours | DES (Cohort 1): 60 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 1A): 60 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 1B): 60 mg Cobimetinib + 960 mg Vemurafenib | DES (Cohort 1C): 60 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 2): 80 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 2A): 100 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 3): 60 mg Cobimetinib + 960 mg Vemurafenib | DES (Cohort 4): 80 mg Cobimetinib + 960 mg Vemurafenib | CES (Cohort 1A): 60 mg Cobimetinib + 720 mg Vemurafenib | CES (Cohort 1B): 60 mg Cobimetinib + 960 mg Vemurafenib |
|---|---|---|---|---|---|---|---|---|---|---|
| Tmax of Vemurafenib on Day -1, Cycle 1 in Participants Previously Treated With Vemurafenib Prior to Enrollment Into This Study | 2.42 (1.3 to 4.5) | 2.50 (0.7 to 7.5) | 3.69 (1.1 to 11) | 4.55 (3.1 to 6.0) | 2.03 (0.9 to 2.5) | 1.65 (1.3 to 2.0) | 1.92 (0.6 to 4.8) | 0.83 (NA to NA) | 2.33 (0.3 to 8.1) | 1.93 (0.6 to 7.5) |
| mcg/mL | DES (Cohort 1B): 60 mg Cobimetinib + 960 mg Vemurafenib | DES (Cohort 1C): 60 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 1D): 60 mg Cobimetinib + 960 mg Vemurafenib | DES (Cohort 2A): 100 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 4): 80 mg Cobimetinib + 960 mg Vemurafenib | CES (Cohort 1A): 60 mg Cobimetinib + 720 mg Vemurafenib | CES (Cohort 1B): 60 mg Cobimetinib + 960 mg Vemurafenib |
|---|---|---|---|---|---|---|---|
| Cmax of Vemurafenib on Day 1, Cycle 1 in BRAFi-naïve Participants | 3.99 ± 73 | 2.31 ± NA | 4.16 ± 78 | 1.25 ± NA | 2.55 ± 170 | 2.60 ± 70 | 2.78 ± 57 |
| mcg/mL | DES (Cohort 1A): 60 mg Cobimetinib + 720 mg Vemurafenib |
|---|---|
| Cmax of Vemurafenib on Day 1, Cycle 1 in Cohort 1A in BRAFi-naïve Participants | 2.08 ± 1.64 |
| hours | DES (Cohort 1A): 60 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 1B): 60 mg Cobimetinib + 960 mg Vemurafenib | DES (Cohort 1C): 60 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 1D): 60 mg Cobimetinib + 960 mg Vemurafenib | DES (Cohort 2A): 100 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 4): 80 mg Cobimetinib + 960 mg Vemurafenib | CES (Cohort 1A): 60 mg Cobimetinib + 720 mg Vemurafenib | CES (Cohort 1B): 60 mg Cobimetinib + 960 mg Vemurafenib |
|---|---|---|---|---|---|---|---|---|
| Tmax of Vemurafenib on Day 1, Cycle 1 in BRAFi-naïve Participants | 5.2 (4.4 to 6.0) | 4.15 (1.0 to 6.0) | 5.17 (NA to NA) | 5.33 (2.0 to 6.2) | 2.08 (NA to NA) | 4.00 (2.0 to 6.0) | 4.00 (2.0 to 6.0) | 4.00 (1.0 to 24) |
| mcg/mL | DES (Cohort 1): 60 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 1A): 60 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 1B): 60 mg Cobimetinib + 960 mg Vemurafenib | DES (Cohort 1C): 60 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 1D): 60 mg Cobimetinib + 960 mg Vemurafenib | DES (Cohort 2): 80 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 2A): 100 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 3): 60 mg Cobimetinib + 960 mg Vemurafenib | DES (Cohort 4): 80 mg Cobimetinib + 960 mg Vemurafenib | CES (Cohort 1A): 60 mg Cobimetinib + 720 mg Vemurafenib | CES (Cohort 1B): 60 mg Cobimetinib + 960 mg Vemurafenib |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cmax of Vemurafenib on Day 14, Cycle 1 | 34.7 ± 41 | 29.4 ± 25 | 43.7 ± 37 | 31.7 ± 42 | 51.3 ± 14 | 43.6 ± 45 | 30.6 ± 53 | 40.9 ± 20 | 33.7 ± 16 | 33.3 ± 58 | 36.3 ± 29 |
| hours | DES (Cohort 1): 60 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 1A): 60 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 1B): 60 mg Cobimetinib + 960 mg Vemurafenib | DES (Cohort 1C): 60 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 1D): 60 mg Cobimetinib + 960 mg Vemurafenib | DES (Cohort 2): 80 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 2A): 100 mg Cobimetinib + 720 mg Vemurafenib | DES (Cohort 3): 60 mg Cobimetinib + 960 mg Vemurafenib | DES (Cohort 4): 80 mg Cobimetinib + 960 mg Vemurafenib | CES (Cohort 1A): 60 mg Cobimetinib + 720 mg Vemurafenib | CES (Cohort 1B): 60 mg Cobimetinib + 960 mg Vemurafenib |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Tmax of Vemurafenib on Day 14, Cycle 1 | 1.98 (0.0 to 7.7) | 2.15 (0.0 to 7.3) | 1.95 (0.0 to 8.0) | 1.98 (0.3 to 6.5) | 0.33 (0.2 to 8.2) | 5.6 (1.7 to 5.6) | 1.05 (0.0 to 6.4) | 1.83 (0.8 to 4.4) | 1.85 (0.1 to 4.0) | 1.17 (0.0 to 7.9) | 1.90 (0.0 to 7.6) |
Tumor response of CR or PR is considered as objective response. CR: disappearance of all target lesions, reduction in short axis \<10 millimeters in pathological lymph nodes (target and non-target lesions); PR: at least a 30 percent (%) decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter. Responses were confirmed by repeat assessments ≥4 weeks after initial documentation.
| percentage of participants | Vemurafenib PD Participants | BRAFi-naïve Participants |
|---|---|---|
| Percentage of Participants With an Objective Response of Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version (V) 1.1 | 15.2 (7.5 to 25.5) | 87.3 (76.7 to 94.4) |
Progressive disease (PD) according to RECIST V 1.1: at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum on study (nadir), including baseline; in addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm; appearance of 1 or more lesions is also considered as progression.
| percentage of participants | Vemurafenib PD Participants | BRAFi-naïve Participants |
|---|---|---|
| Percentage of Participants With Disease Progression According to RECIST V 1.1 | 36.4 | 3.2 |
Duration of response, defined as the time from first occurrence of a documented objective response until the time of disease progression, as determined by investigator review of tumor assessments using RECIST v 1.1, or death from any cause during the study (that is within 30 days after the last dose of study treatment).
| months | Vemurafenib PD Participants | BRAFi-naïve Participants |
|---|---|---|
| Median Duration of Response (DOR) | 6.8 (4.9 to 10.4) | 14.3 (9.7 to 23) |
OS was defined as the time from the date of randomization to the date of death due to any cause. Participants were censored at the last date of tumor measurement, the last date in the study drug log, or the date of last follow-up. OS analyzed using Kaplan-Meier estimate.
| months | Vemurafenib PD Participants | BRAFi-naïve Participants |
|---|---|---|
| Overall Survival (OS) | 8.5 (1.6 to 76.4) | 31.8 (2.7 to 69.2) |
The pharmacodynamic effect of cobimetinib in combination with vemurafenib was assessed by measuring changes in FDG uptake as characterized by the lean body mass corrected (LBM) maximum standardized uptake value (SUV max) measurement using FDG-PET. Post-baseline timepoint Cycle 1 was averaged between Days 10 to 14 and Cycle 2 for Days 14+7.
| Percent change in FDG-PET | Vemurafenib PD Participants | BRAFi-naïve Participants |
|---|---|---|
| Baseline (n=63,63) | 8.75 ± 5.55 | 8.19 ± 5.00 |
| Percent Change at Cycle 1 (Days 10-14) (n=59,60) | -43.33 ± 26.00 | -65.74 ± 14.82 |
| Percent Change at Cycle 2 (Days 14+7) (n=50,56) | -33.09 ± 35.18 | -70.73 ± 17.05 |
Changes in effector molecules of the MAPK pathway that are directly or indirectly affected by BRAF and MEK inhibition (including but not limited to ERK and phosphorylated ERK and MEK) by IHC using biopsies at baseline, between Days 10-14 of Cycle 1, and at disease progression. IHC is a staining process performed on fresh/frozen tumor tissue samples.
| participants | Vemurafenib PD Participants | BRAFi-naïve Participants |
|---|---|---|
| Pharmacodynamics: Number of Participants With Mitogen-Activated Protein Kinase (MAPK) Inhibition, as Assessed by Immunohistochemistry (IHC) | 7 | 5 |
Collected over Up to 82 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vemurafenib PD Participants | — | 21/66 (31.8%) | 64/66 (97%) |
| BRAFi-naïve Participants | — | 36/63 (57.1%) | 63/63 (100%) |
| Cobimetinib Monotherapy (100 mg or 60 mg) | — | 0/2 (0%) | 2/2 (100%) |
| Event | Vemurafenib PD Participants | BRAFi-naïve Participants | Cobimetinib Monotherapy (100 mg or 60 mg) |
|---|---|---|---|
| Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 4/66 | 7/63 | 0/2 |
| SeizureNervous system disorders | 1/66 | 5/63 | 0/2 |
| CellulitisInfections and infestations | 0/66 | 4/63 | 0/2 |
| PyrexiaGeneral disorders | 1/66 | 2/63 | 0/2 |
| PneumoniaInfections and infestations | 2/66 | 2/63 | 0/2 |
| SepsisInfections and infestations | 0/66 | 2/63 | 0/2 |
| Urinary tract infectionInfections and infestations | 0/66 | 2/63 | 0/2 |
| HyponatraemiaMetabolism and nutrition disorders | 0/66 | 2/63 | 0/2 |
| Back painMusculoskeletal and connective tissue disorders | 0/66 | 2/63 | 0/2 |
| Renal failureRenal and urinary disorders | 0/66 | 2/63 | 0/2 |
| Event | Vemurafenib PD Participants | BRAFi-naïve Participants | Cobimetinib Monotherapy (100 mg or 60 mg) |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 31/66 | 52/63 | 2/2 |
| FatigueGeneral disorders | 18/66 | 46/63 | 1/2 |
| Photosensitivity reactionSkin and subcutaneous tissue disorders | 12/66 | 44/63 | 0/2 |
| NauseaGastrointestinal disorders | 22/66 | 37/63 | 1/2 |
| RashSkin and subcutaneous tissue disorders | 18/66 | 33/63 | 1/2 |
| Dermatitis acneiformSkin and subcutaneous tissue disorders | 6/66 | 22/63 | 1/2 |
| AlopeciaSkin and subcutaneous tissue disorders | 7/66 | 9/63 | 1/2 |
| VomitingGastrointestinal disorders | 13/66 | 30/63 | 1/2 |
| Abdominal painGastrointestinal disorders | 10/66 | 13/63 | 1/2 |
| ConstipationGastrointestinal disorders | 10/66 | 13/63 | 1/2 |
Demographic data was not reported across dose/regimen cohort per final analysis, as it was pooled across separately for vemurafenib-PD and BRAFi-naive participants who received cobimetinib and vemurafenib. Data is presented based on the final CSR. As of 2017 per-cohort data were not collected
| Age, Continuous(years) | Vemurafenib PD Participants | BRAFi-naïve Participants | Cobimetinib Monotherapy (100 mg or 60 mg) | Total |
|---|---|---|---|---|
| Mean | 53.0 ± 14.8 | 54.0 ± 13.0 | 62.5 ± 9.2 | 53.6 ± 13.9 |
| Sex: Female, Male(Participants) | Vemurafenib PD Participants | BRAFi-naïve Participants | Cobimetinib Monotherapy (100 mg or 60 mg) | Total |
|---|---|---|---|---|
| Female | 24 | 28 | 1 | 53 |
| Male | 42 | 35 | 1 | 78 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2011 to primary completion in Oct 2013, 31 months.
Results were first posted in Jun 2016, 2 years 8 months after primary completion.
Of 225 industry-sponsored phase 1 interventional studies under Melanoma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 66. This study's 31 months is below that.
Counting every sponsor, half of 411 studies reached it within 49 months; a quarter within 31 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cobimetinib · Vemurafenib